US-Chinese pharma dispute settles at ICC
US and Chinese pharma companies have settled an ICC arbitration over the licensing of rights to promote a breast cancer drug in Greater China.
To read more
Subscribe to Global Arbitration Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Arbitration Review experts.